Exicure, Inc. SEC filings XCUR
Exicure, Inc. has 532 filings in SEC EDGAR's recent list, going back to Mar 21, 2017. Its latest annual report, Form 10-K, was filed on Mar 25, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 16, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-Q | Filing | May 15, 2026 | Mar 31, 2026 |
| EFFECT | Filing | Jul 22, 2025 | — |
| CORRESP | Letter to the SEC | Jul 18, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 17, 2025 | — |
| NT 10-Q | Filing | May 15, 2025 | May 15, 2025 |
| NT 10-Q | Filing | May 15, 2024 | May 15, 2024 |
| NT 10-K | Filing | Apr 1, 2024 | Apr 1, 2024 |
| NT 10-Q | Filing | Nov 14, 2023 | Nov 14, 2023 |
| NT 10-Q | Filing | May 15, 2023 | May 15, 2023 |
| EFFECT | Filing | Jul 20, 2022 | — |
| CORRESP | Letter to the SEC | Jul 18, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 18, 2022 | — |
| NT 10-Q | Filing | Nov 15, 2021 | Sep 30, 2021 |
| EFFECT | Filing | Jan 7, 2021 | — |
| CORRESP | Letter to the SEC | Jan 5, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2020 | — |
| EFFECT | Filing | Jun 9, 2020 | — |
| EFFECT | Filing | Jun 9, 2020 | — |
| CERT | Filing | Jul 30, 2019 | — |
| 8-A12B | Filing | Jul 30, 2019 | — |
| EFFECT | Filing | Jul 24, 2019 | — |
| CORRESP | Letter to the SEC | Jul 22, 2019 | — |
| CORRESP | Letter to the SEC | Jul 11, 2019 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2019 | — |
| EFFECT | Filing | Oct 5, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 4, 2018 | — |
| CORRESP | Letter to the SEC | Oct 3, 2018 | — |
| D | Filing | Aug 31, 2018 | — |
| EFFECT | Filing | Feb 6, 2018 | — |
| CORRESP | Letter to the SEC | Feb 5, 2018 | — |
| CORRESP | Letter to the SEC | Jan 26, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 24, 2018 | — |
| CORRESP | Letter to the SEC | Jan 12, 2018 | — |
| CT ORDER | Filing | Jan 11, 2018 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 17, 2017 | — |
| CORRESP | Letter to the SEC | Nov 7, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2017 | — |
| D | Filing | Oct 10, 2017 | — |
| D | Filing | Oct 10, 2017 | — |
| SC 14F1 | Information statement | Aug 8, 2017 | — |
| D | Filing | Jul 3, 2017 | — |
| UPLOAD | Letter from the SEC | May 3, 2017 | — |
| CORRESP | Letter to the SEC | Apr 20, 2017 | — |
| 10-12G/A | Amendment no. 1 to form 10-12g | Apr 20, 2017 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2017 | — |
| 10-12G | General form for registration of securities | Mar 21, 2017 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XCUR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1698530
- Former names
- Max-1 Acquisition Corp (until Sep 28, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.